Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases
Immunology Letters · 2025-06 · 273 · 106983
DOI: 10.1016/j.imlet.2025.106983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology Letters, 2025-06. Verfasst von Jin Qin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China. Hauptthemen laut MEDLINE: Myasthenia Gravis, Receptors, Fc, Autoimmune Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 17 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China.
- Department of Neurology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, Henan, China. Electronic address: zhangjiewen9900@126.com.
Zitieren
APA
Qin, J., Li, W., Yuan, L., Liu, H., Pang, R., & Zhang, J. (2025). Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases. Immunology Letters, 273, 106983. https://doi.org/10.1016/j.imlet.2025.106983
Vancouver
Qin J, Li W, Yuan L, Liu H, Pang R, Zhang J. Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases. Immunology Letters. 2025;273:106983. doi:10.1016/j.imlet.2025.106983
BibTeX
@article{Qin2025,
author = {Qin, Jin and Li, Wei and Yuan, Lipin and Liu, Huiqin and Pang, Rui and Zhang, Jiewen},
title = {Efficacy and safety of efgartigimod in patients with neurological autoimmune diseases},
journal = {Immunology Letters},
year = {2025},
volume = {273},
pages = {106983},
doi = {10.1016/j.imlet.2025.106983}
}
EUVIMED